|
When US WorldMeds is showcased in the media or you need access to a press release, you can come here to our Newsroom. We’re happy to provide immediate access to the latest information and resources about our company. It’s quick. It’s easy. And it’s a must for journalists and others who want up-to-the-minute facts about US WorldMeds.
US WorldMeds in the news:
June 2008
US WorldMeds Completes Phase III Trial of Lofexidine for Treatment of Opiate Withdrawal Symptoms Click here to view.
May 2008
US WorldMeds Completes Development of Instantaneous Reconstitution Dantrolene Sodium for Injection Product. Click here to view.
WINTER 2008
AAAASF Newsletter | ASF SOURCE - (pg7)
US WorldMeds, a closely held Delaware limited liability company, has introduced a generic equivalent to Dantrium® IV
that is now available through wholesalers and GPOs. Click here to view.
July 2007
US WorldMeds received FDA approval of its US marketing license (ANDA) for Dantrolene Sodium for Injection. See the Orange Book (“Approved Drug Products with Therapeutic Equivalence Evaluations”). This product is AP rated.
December 2006
The Courier-Journal, US WorldMeds Chief Executive Officer shares vision for company. Click here to review.
October 2006
US WorldMeds announces that it is enrolling study subjects in a Phase 3 clinical trial to determine the safety and efficacy of Lofexidine in relieving the debilitating withdrawal symptoms associated with opiate detoxification. Click here to view.
August 2005
DSM Pharmaceuticals, Inc. and US WorldMeds, LLC announce signing of commercial supply agreement. Click here to view.
January 2004
Visions Newsletter, (see page 2). Click here to view.
November 2003
The Wall Street Journal, November 18 2003. Members of the Wall Street Journal Online can access and view the article by searching under the keyword "detoxify" and date "11/18/03". Peter Sanders is the columnist.
November 2003
Britannia signs agreement with US WorldMeds to bring first non-opiate drug addiction treatment to the US.
Click here for a copy of Britannia's press release. (29 KB)
June 2003
New study shows the potential of BritLofex™ in preventing opiate relapse.
Click here for a copy of Britannia's press release. (55 KB)
June 2002
Trial of Britannia Pharmaceuticals’ BritLofex™ stopped early due to overwhelming efficacy.
Click here for a copy of Britannia's press release. (47KB)
Meetings/Tradeshows:
US WorldMeds will be exhibiting at the following upcoming meetings/tradeshows. Please give us a call to set up a meeting time, or just stop by our booth.
|
